Novel bispecific monoclonal antibody explored for treating wet AMD

SAN FRANCISCO — Single and multiple-dose injections of a bispecific monoclonal antibody were deemed “safe and well tolerated” in patients with difficult to treat neovascular age-related macular degeneration.Reporting results of a phase 1 study of RG7716 (Roche) at the American Society of Retina Specialists annual meeting, Pravin U. Dugel, MD, described the agent as able to “potently and selectively” neutralize VEGF and angiopoietin-2.